Katherine Bowdish, PhD is Vice President Global R&D and Head of Sanofi Sunrise, an investment and company co-creation vehicle advancing early stage cutting-edge science. Sunrise partners with world-class innovators in unique and deeply collaborative relationships, simultaneously serving as an investor and first partner to accelerate transformative treatments to patients.
Katherine has extensive experience in life science, prior to her current role as a serial entrepreneur; founding, building and leading several early-stage companies focused on biological therapies. Past positions include President & CSO, Permeon Biologics; Co-founder, President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals; Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.
Katherine currently serves on the Board of Directors of Warp Drive Bio, Portal Instruments, and Thermalin; past board positions include MyoKardia, Anaphore and Prolifaron.
She received her PhD from Columbia University College of Physicians and Surgeons, and BS from the College of William and Mary.